NCT04398745: Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function
NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
NCT04843579: Phase 2: Selinexor in Combination With Clarithromycin, Pom & Dex RRMM - ClaSPd
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS RRMM Myeloma
NCT04398485: Phase 1: A Study of ION251 Administered to Patients With Relapsed/Refractory Myeloma
NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma
NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd
NCT03777410: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
NCT03424603: Phase 1: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, B-Cell Malignancies
NCT03158688: Phase 3 - Carfilzomib, Daratumumab and Dexa for relapsed Multiple Myeloma. (CANDOR)
NCT03289299 : Phase 2 - Agg. Smoldering Curative Approach Eval. Novel Therapies & Transplant ASCENT
NCT03314181: Phase 2 - Venetoclax, Daratumumab and Dex (+/- Bortezomib) in RRMM Multiple Myeloma
NCT02773030: Phase 1/2: CC-220 Monotherapy and in Combination With Treatments in NDMM / RRMM
NCT02343042: Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)
NCT02465060: Phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With RRMM
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
NCT01239797: Phase 3: Lenalidomide and Dexamethasone With or Without Elotuzumab RRMM (ELOQUENT - 2)